Topic

Blue Cross Blue Shield (BCBS Association)

A collection of 1062 issues

Work With Your Doctor to Get Tavalisse (Fostamatinib) Covered by Blue Cross Blue Shield in Pennsylvania: Complete Prior Authorization Guide

Quick Answer: Getting Tavalisse Covered in Pennsylvania To get Tavalisse (fostamatinib) covered by Blue Cross Blue Shield in Pennsylvania, you'll need prior authorization from a hematologist or oncologist documenting chronic ITP diagnosis, platelet count below 30,000/μL, and failure of first-line therapies (corticosteroids, IVIG, or TPO agonists)
6 min read

How to Get Aldurazyme (laronidase) Covered by Blue Cross Blue Shield in California: Complete Guide to Prior Authorization and Appeals

Answer Box: Getting Aldurazyme Coverage in California Blue Shield of California covers Aldurazyme (laronidase) as a specialty drug requiring prior authorization for MPS I patients. The fastest path to approval: (1) Gather genetic/enzymatic confirmation of MPS I diagnosis, (2) Document baseline disease severity and prior treatment failures, (3) Submit
6 min read

How to Get Cometriq (Cabozantinib) Covered by Blue Cross Blue Shield in Ohio: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Cometriq Covered in Ohio Blue Cross Blue Shield of Ohio (Anthem BCBS OH) requires prior authorization for Cometriq (cabozantinib capsules) for progressive/metastatic medullary thyroid carcinoma. First step: Verify your diagnosis meets criteria (confirmed MTC with progression, no active bleeding/GI issues). Fastest path: Submit PA via
6 min read

How to Get Cresemba (Isavuconazole) Covered by Blue Cross Blue Shield in California: Prior Authorization Forms, Appeals & Timelines

Answer Box: Getting Cresemba Covered by Blue Cross Blue Shield in California Blue Cross Blue Shield California requires prior authorization for all Cresemba (isavuconazole) requests. Submit clinical documentation showing confirmed invasive aspergillosis or mucormycosis (ICD-10 codes B46.0-B46.9) via AuthAccel portal or fax. If denied, file an internal appeal
6 min read